{"id":119294,"date":"2026-04-10T09:26:00","date_gmt":"2026-04-10T07:26:00","guid":{"rendered":"https:\/\/cms.munich-startup.net\/?p=119294"},"modified":"2026-04-14T09:45:44","modified_gmt":"2026-04-14T07:45:44","slug":"tubule-exit","status":"publish","type":"post","link":"https:\/\/cms.munich-startup.net\/en\/119294\/tubule-exit\/","title":{"rendered":"Tubules purchased from American pharmaceutical giant"},"content":{"rendered":"<div class=\"entry-content\">\n<p>The sale of Tubulis is one of the biggest exits in the German biotech scene. The Munich-based company with <a href=\"\/en\/day\/tubules\/\">Unicorn status<\/a> The company is selling its assets to the US pharmaceutical giant Gilead for up to \u20ac4.3 billion ($5 billion). \u20ac2.7 billion ($3.15 billion) will be paid directly, while a further \u20ac1.6 billion ($1.85 billion) is contingent on achieving certain milestones. The transaction is expected to close in the second quarter of 2026.<\/p>\n\n\n\n<p>tubules develop <a href=\"https:\/\/tubulis.com\/technology\/\" target=\"_blank\" rel=\"noreferrer noopener\">Antibody-drug conjugates (ADCs)<\/a>, a modern form of cancer therapy. These therapies target tumor cells more precisely than traditional chemotherapies. The company combines antibodies and cytotoxic agents to create particularly stable drugs. Among its most important projects is TUB-040, which is currently in clinical development for ovarian and lung cancer. TUB-030 is also showing promising initial data in various solid tumors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Strategic expansion of oncology<\/h2>\n\n\n\n<p>With this acquisition, Gilead is strategically expanding its expertise in the field of oncology. Tubulis&#039; technologies and programs complement the company&#039;s existing pipeline. At the same time, the American company gains access to a platform designed to deliver various drugs precisely to tumors.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cThe agreement to acquire Tubulis is a significant milestone for Gilead in the field of oncology. The company brings with it a clinical-stage candidate representing a potential new therapy for ovarian cancer, as well as a next-generation ADC platform and a promising early-stage pipeline. Today\u2019s agreement follows a two-year collaboration with Tubulis, which has impressed us with their programs and research capabilities. Integrating this potential into Gilead would further enhance what is already the strongest and most diverse pipeline in our company\u2019s history.\u201d<\/p>\n<\/blockquote>\n\n\n\n<p>explained <strong>Daniel O&#039;Day<\/strong>, Chairman and CEO of Gilead Sciences.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Signal effect for the Munich location<\/h2>\n\n\n\n<p>Following the completion of the project, Tubulis will remain an independent research unit within Gilead. Munich will thus further develop as a central innovation hub for ADC technologies. The company will leverage its integrated expertise in research, manufacturing, and clinical development to advance new therapies.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cFrom the outset, we were convinced that our conjugation technology platforms could have a far-reaching impact on the entire ADC field, and the initial data from TUB-040 have reinforced this conviction. Joining forces with Gilead allows us to build on this foundation within a company that possesses deep scientific expertise, global development capabilities, and the scale necessary to translate innovations into medicines for patients worldwide. Through our existing collaboration, Gilead has already recognized the potential of our technologies, and together we are well-positioned to accelerate the development of our ADC pipeline. I am deeply grateful to the Tubulis team, our board, our investors, and partners for their dedication and for helping to make this milestone possible.\u201d<\/p>\n<\/blockquote>\n\n\n\n<p>says <strong>Dominik Schumacher<\/strong>, CEO and co-founder of Tubulis.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Munich-based biotech unicorn Tubulis is being sold to US corporation Gilead for a billion-dollar sum. <\/p>","protected":false},"author":42,"featured_media":113806,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5633,1],"tags":[371,222,4321,243,4001,223],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Tubulis von amerikanischem Pharma-Riesen gekauft - Munich Startup<\/title>\n<meta name=\"description\" content=\"Der Krebsspezialist Tubulis aus M\u00fcnchen wird f\u00fcr bis zu 4,3 Milliarden Euro an den US-Pharmakonzern Gilead verkauft.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cms.munich-startup.net\/en\/119294\/tubule-exit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tubulis von amerikanischem Pharma-Riesen gekauft - Munich Startup\" \/>\n<meta property=\"og:description\" content=\"Der Krebsspezialist Tubulis aus M\u00fcnchen wird f\u00fcr bis zu 4,3 Milliarden Euro an den US-Pharmakonzern Gilead verkauft.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.munich-startup.net\/en\/119294\/tubule-exit\/\" \/>\n<meta property=\"og:site_name\" content=\"Munich Startup\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/munichstartup\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-10T07:26:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-14T07:45:44+00:00\" \/>\n<meta name=\"author\" content=\"Saskia Doll\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:site\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Saskia Doll\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.munich-startup.net\/119294\/tubulis-exit\/\",\"url\":\"https:\/\/cms.munich-startup.net\/119294\/tubulis-exit\/\",\"name\":\"Tubulis von amerikanischem Pharma-Riesen gekauft - Munich Startup\",\"isPartOf\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.munich-startup.net\/119294\/tubulis-exit\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.munich-startup.net\/119294\/tubulis-exit\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2025\/10\/Tubulis2.jpg\",\"datePublished\":\"2026-04-10T07:26:00+00:00\",\"dateModified\":\"2026-04-14T07:45:44+00:00\",\"author\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/a297bffde6879f56c9ff7b04d9af60b5\"},\"description\":\"Der Krebsspezialist Tubulis aus M\u00fcnchen wird f\u00fcr bis zu 4,3 Milliarden Euro an den US-Pharmakonzern Gilead verkauft.\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.munich-startup.net\/119294\/tubulis-exit\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.munich-startup.net\/119294\/tubulis-exit\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/119294\/tubulis-exit\/#primaryimage\",\"url\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2025\/10\/Tubulis2.jpg\",\"contentUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2025\/10\/Tubulis2.jpg\",\"width\":2400,\"height\":2147,\"caption\":\"Das Management-Team von Tubulis, (v. l. n. r.): Ingo Lehrke (CBO), G\u00fcnter Fingerle-Rowson (CMO), Dominik Schumacher (CEO), Jonas Helma-Smets (CSO), Matthew Norkunas (CFO) und Bj\u00f6rn Hock (CDO)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.munich-startup.net\/119294\/tubulis-exit\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cms.munich-startup.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tubulis von amerikanischem Pharma-Riesen gekauft\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cms.munich-startup.net\/#website\",\"url\":\"https:\/\/cms.munich-startup.net\/\",\"name\":\"Munich Startup\",\"description\":\"Das offizielle Startup-Portal f\u00fcr M\u00fcnchen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cms.munich-startup.net\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/a297bffde6879f56c9ff7b04d9af60b5\",\"name\":\"Saskia Doll\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3cbbe2dd459d277864bc6c7477d0bdf8?s=96&d=blank&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3cbbe2dd459d277864bc6c7477d0bdf8?s=96&d=blank&r=g\",\"caption\":\"Saskia Doll\"},\"url\":\"https:\/\/cms.munich-startup.net\/en\/author\/doll\/\"}]}<\/script>\n<meta property=\"og:image\" content=\"https:\/\/cms.munich-startup.net\/en\/wp-content\/uploads\/2025\/10\/Tubulis2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2400\" \/>\n\t<meta property=\"og:image:height\" content=\"2147\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tubules purchased by American pharmaceutical giant - Munich Startup","description":"Munich-based cancer specialist Tubulis is being sold to the US pharmaceutical company Gilead for up to 4.3 billion euros.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cms.munich-startup.net\/en\/119294\/tubule-exit\/","og_locale":"en_US","og_type":"article","og_title":"Tubulis von amerikanischem Pharma-Riesen gekauft - Munich Startup","og_description":"Der Krebsspezialist Tubulis aus M\u00fcnchen wird f\u00fcr bis zu 4,3 Milliarden Euro an den US-Pharmakonzern Gilead verkauft.","og_url":"https:\/\/cms.munich-startup.net\/en\/119294\/tubule-exit\/","og_site_name":"Munich Startup","article_publisher":"https:\/\/www.facebook.com\/munichstartup\/","article_published_time":"2026-04-10T07:26:00+00:00","article_modified_time":"2026-04-14T07:45:44+00:00","author":"Saskia Doll","twitter_card":"summary_large_image","twitter_creator":"@munich_startup","twitter_site":"@munich_startup","twitter_misc":{"Written by":"Saskia Doll","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.munich-startup.net\/119294\/tubulis-exit\/","url":"https:\/\/cms.munich-startup.net\/119294\/tubulis-exit\/","name":"Tubules purchased by American pharmaceutical giant - Munich Startup","isPartOf":{"@id":"https:\/\/cms.munich-startup.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.munich-startup.net\/119294\/tubulis-exit\/#primaryimage"},"image":{"@id":"https:\/\/cms.munich-startup.net\/119294\/tubulis-exit\/#primaryimage"},"thumbnailUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2025\/10\/Tubulis2.jpg","datePublished":"2026-04-10T07:26:00+00:00","dateModified":"2026-04-14T07:45:44+00:00","author":{"@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/a297bffde6879f56c9ff7b04d9af60b5"},"description":"Munich-based cancer specialist Tubulis is being sold to the US pharmaceutical company Gilead for up to 4.3 billion euros.","breadcrumb":{"@id":"https:\/\/cms.munich-startup.net\/119294\/tubulis-exit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.munich-startup.net\/119294\/tubulis-exit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/119294\/tubulis-exit\/#primaryimage","url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2025\/10\/Tubulis2.jpg","contentUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2025\/10\/Tubulis2.jpg","width":2400,"height":2147,"caption":"Das Management-Team von Tubulis, (v. l. n. r.): Ingo Lehrke (CBO), G\u00fcnter Fingerle-Rowson (CMO), Dominik Schumacher (CEO), Jonas Helma-Smets (CSO), Matthew Norkunas (CFO) und Bj\u00f6rn Hock (CDO)"},{"@type":"BreadcrumbList","@id":"https:\/\/cms.munich-startup.net\/119294\/tubulis-exit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cms.munich-startup.net\/"},{"@type":"ListItem","position":2,"name":"Tubulis von amerikanischem Pharma-Riesen gekauft"}]},{"@type":"WebSite","@id":"https:\/\/cms.munich-startup.net\/#website","url":"https:\/\/cms.munich-startup.net\/","name":"Munich Startup","description":"The official startup portal for Munich","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cms.munich-startup.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/a297bffde6879f56c9ff7b04d9af60b5","name":"Saskia Doll","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3cbbe2dd459d277864bc6c7477d0bdf8?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3cbbe2dd459d277864bc6c7477d0bdf8?s=96&d=blank&r=g","caption":"Saskia Doll"},"url":"https:\/\/cms.munich-startup.net\/en\/author\/doll\/"}]},"og_image":[{"width":2400,"height":2147,"url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2025\/10\/Tubulis2.jpg","type":"image\/jpeg"}]},"_showyear":"","_inactive":"","_show_financing":"","_hide_on_map":"","_edit_lock":"1776152745:25","_edit_last":"25","_yoast_wpseo_focuskw":"Tubulis","_yoast_wpseo_metadesc":"Der Krebsspezialist Tubulis aus M\u00fcnchen wird f\u00fcr bis zu 4,3 Milliarden Euro an den US-Pharmakonzern Gilead verkauft.","_yoast_wpseo_linkdex":"81","_thumbnail_id":"113806","wbounce_status":"default","_yoast_wpseo_primary_category":"5633","_yoast_wpseo_focuskw_text_input":"","_yoast_wpseo_content_score":"90","ms_image_format":"contentwidth","_ms_image_format":"field_5cb8587572c8b","ms_dachzeile":"","_ms_dachzeile":"field_5cd9b7f365df5","ms_bump_post_date":"","_ms_bump_post_date":"field_5d1341edcf42a","guest_author_name":"","_guest_author_name":"field_5cee78a6016f9","guest_author_image":"","_guest_author_image":"field_5cee7914016fb","guest_author_description":"","_guest_author_description":"field_5cee78dd016fa","ms_post_image_caption":"","_ms_post_image_caption":"field_5f735b0735284","ms_post_image_credit":"","_ms_post_image_credit":"field_5f735b1435285","suppress_startupbox":"1","_suppress_startupbox":"field_60a64b0b6efc6","_yoast_wpseo_estimated-reading-time-minutes":"2","_wp_old_date":"","_yoast_wpseo_title":"","_yoast_wpseo_wordproof_timestamp":"","footnotes":"","easy_language_simplification_original_id":"","easy_language_source_language":"","easy_language_simplification_language":"","easy_language_api":"","easy_language_prevent_automatic_mode":"","_wp_old_slug":"","_wp_trash_meta_status":"","_wp_trash_meta_time":"","easy_language_simplification_state_changed_from":"","easy_language_de_EL_changed":"","ms_competition_deadline":"","_ms_competition_deadline":"","_wpbitly":"","enclosure":"","_yoast_wpseo_meta-robots-noindex":"","_yoast_wpseo_meta-robots-nofollow":"","wbounce_template":"","wbounce_title":"","wbounce_text":"","wbounce_cta":"","wbounce_url":"","wbounce_override":"","_yoast_wpseo_opengraph-title":"","_yoast_wpseo_opengraph-description":"","_oembed_7131efca3705e16bd9da2c41df237660":"","_oembed_time_7131efca3705e16bd9da2c41df237660":"","_pprredirect_type":"","_pprredirect_url":"","_yoast_wpseo_opengraph-image":"","_yoast_wpseo_opengraph-image-id":"","_newsletterglue":"","easy_language_text_language":"","_wp_desired_post_slug":"","_relevanssi_noindex_reason":"","_links":{"self":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/119294"}],"collection":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/users\/42"}],"replies":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/comments?post=119294"}],"version-history":[{"count":4,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/119294\/revisions"}],"predecessor-version":[{"id":119537,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/119294\/revisions\/119537"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media\/113806"}],"wp:attachment":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media?parent=119294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/categories?post=119294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/tags?post=119294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}